Search

May 10, 2019 10:28 am I had the privilege to be at FDA during a remarkable period of political and scientific opportunity. On the one hand, we had the tailwind [...]

Researchers at the University of Saskatchewan have discovered how a previously overlooked gene is involved in antimicrobial resistance - a growing global issue that threatens the health and welfare of both humans and animals. The gene encodes for an enzyme named EstT and is capable of "turning off" or inactivating macrolides, a class of antibiotic drugs commonly used to treat disease in cattle and other livestock. [Extracted from the article]

This article presents news briefs related to the treatment of Alzheimer's disease. One of the snippets report that Neurologix Inc. has licensed a promising new gene for the treatment of Alzheimer's and other central nervous system disorders from Keio University in Tokyo, Japan as part of a strategic move to broaden its product portfolio. Another snippet presents information on the U.S. National Institute on Aging that has awarded $9 million to the University of California in Irvine, California to support research into Alzheimer's disease and to help fund the development of pioneering treatments. The five-year Alzheimer's Disease Research Center grant, which will support more than 30 University of California, Irvine faculty investigators, renews an expiring $6 million grant from the National Institute on Aging.

The article offers news briefs related to pharmaceutical industry. It was found that the gene APOE4 heightens the risk of developing Alzheimer disease later in life. Immuno-Biological Laboratories Co. Ltd. has sold the rights to its Alzheimer's antibodies. GlaxoSmithKline and Biovail Corp. have been given the signal to sell a generic version of Wellbutrin XL for major depressive disorder, by the Food and Drug Administration.

The article presents news briefs about clinical developments related to psychiatry. The Apaf-1 gene related to major depression is discovered by researchers working at Myriad Genetics Inc. This gene makes the (Apaf-1) protein, which is an activator of a cascade of events leading to the destruction of a cell. A study about the investigational drug SEP-225289, which is used for the treatment of major depressive disorder, has been initiated by Sepracor Inc. This drug has the potential to be a leading drug candidate in the newly emerging field of triple reuptake inhibitors.